Surgically implanted bone growth stimulator
Maintains a Low Profile while stimulating bone growth
The OsteoGen surgically implanted bone growth stimulator is a useful adjunct for treating nonunions where surgery is already planned or where patient noncompliance may be a factor with pulsed electromagnetic fields (PEMF). Because the OsteoGen is totally implanted, your patient is assured of the therapeutic treatment at the nonunion site.
- Hip and Femur
- Shoulder and Elbow
In one 10-year follow-up clinical study, the EBI OsteoGen Implantable Stimulator
success rate in healing tibia nonunions.1
30cm long lead option allows positioning of generator in areas more suitable for placement.
1. PJ Cundy, FRACS, DC Paterson, MD, FRCS, FRACS. A Ten-Year Review of Treatment of Delayed Union and Nonunion with an Implanted Bone Growth Stimulator. Clin Orthop Relat Res. 1990 Oct; (259): 216-22.
*MRI safety information has not yet been established for OsteoGen Implantable Bone Growth Stimulators. The FDA approved device trade name is the EBI OsteoGen Implantable Growth Stimulator.
INDICATIONS AND USAGE
The Stimulator is indicated in the treatment of long bone nonunions. A nonunion is considered to be established when the fracture site shows no visibly progressive signs of healing. The original 1980 PMA included two clinical studies; neither was designed for long-term follow-up. In the first study (N=30) the patients were followed for a minimum of ten (10) years, with an overall follow-up rate of 48.2%. The long-term success rate was 66.7%. This calculation excludes the initial treatment successes not followed for ten (10) years (N=11). The second study (N=107) followed the patients for a minimum of four (4) years with overall follow-up rate of 25.6%. The long-term success rate was 38.8%. This calculation excludes the initial treatment successes not followed for four (4) years (N=58). In both studies, patients had difficult nonunion fractures: 0.7 and 1.5 number of average prior surgeries, average 28.4 and 24.3 months (median 24 and 16) disability since original injury, and 43.3% and 24.3% infected prior to treatment, respectively.
There are no known contraindications to the use of this device, however, due to insufficient clinical experience, it is not recommended that it be used in the following conditions: pathological fractures due to malignant tumors or in the presence of active osteomyelitis.
56 East Bell Drive
P.O. Box 587
Warsaw, Indiana 46581 USA
Tailored resources for your patients.
Find videos, articles, and interactive content to guide your patients throughout their surgical journey on ReadyPatient.com, our deidcated patient recovery site.
All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.
This material is intended for health care professionals. Distribution to any other recipient is prohibited.
For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert and information on this website. To obtain a copy of the current Instructions for Use (IFU) for full prescribing and risk information, please call 1-800-348-2759, press 4 for 411 Technical Support.